| Ms Cristina Elizabeth Correa-barron, | |
|
3502 S Mason Ave, Apt #4k, Tacoma, WA 98409-8541 | |
| (818) 454-3658 | |
| Not Available |
| Full Name | Ms Cristina Elizabeth Correa-barron |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 3502 S Mason Ave, Tacoma, Washington |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1194072546 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Ms Cristina Elizabeth Correa-barron, 3502 S Mason Ave, Apt # 4k, Tacoma, WA 98409-8541 Ph: (818) 454-3658 | Ms Cristina Elizabeth Correa-barron, 3502 S Mason Ave, Apt #4k, Tacoma, WA 98409-8541 Ph: (818) 454-3658 |
News Archive
A group of researchers from EPFL's Global Health Institute (GHI) and Inserm (Institut National de la Sant- et de la Recherche M-dicale, the French government agency for biomedical research) has discovered that a class of chemotherapy drugs originally designed to inhibit key signaling pathways in cancer cells also kills the parasite that causes malaria. The discovery could quickly open up a whole new strategy for combating this deadly disease.
There is no cure for Huntington's, a neurodegenerative disorder that now afflicts 30,000 Americans, with another 150,000 at risk. The fatal disease, which is genetically inherited, usually strikes in midlife and causes uncontrolled movements, loss of cognitive function and emotional disturbance.
KAEL-GemVax, a leading oncology biopharmaceutical company, today announced that results from a Phase II trial (CTN-2006) in Stage III non-small cell lung cancer (NSCLC) patients vaccinated with the telomerase peptide GV1001 after chemoradiotherapy and an 8-year update from a phase I/II trial have been published in the November issue of Clinical Cancer, the journal of the American Association for Cancer Research.
Patients at risk of heart attacks and strokes may be spotted earlier thanks to a diagnosis tool that uses near-infrared light to identify high-risk arterial plaques, according to research carried out at WMG, University of Warwick, the Baker Institute and Monash University.
› Verified 2 days ago
Andrea Lynn Rottier, LL Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 4301 S Pine St, Ste 219, Tacoma, WA 98409 Phone: 253-476-6550 | |
Janet Kobayashi-hobson, CCC Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 315 Martin Luther King Jr Way, Tacoma, WA 98405 Phone: 253-403-1000 | |
Christine L Camp, PH.D., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2106 E 44th St, Tacoma, WA 98404 Phone: 253-571-2908 | |
Ann S Lewis, B.S. Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1202 S 76th St, Tacoma, WA 98408 Phone: 253-571-4579 | |
Angela Curtis, M.S., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 9040 Jackson Ave, Tacoma, WA 98431 Phone: 253-968-7919 | |
Porsche Maneice, SLP Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 242 St Helens Ave, Tacoma, WA 98402 Phone: 253-627-3833 | |
Peggy Lesniak, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1310 S Union Ave Ste A100, Tacoma, WA 98405 Phone: 253-383-2423 |